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 Review: Provider Practice and User Behavior Interventions to Improve Prompt and Effective 
Treatment of Malaria: Do We Know What Works? 
 Lucy A.  Smith , *  Caroline  Jones ,  Sylvia  Meek , and  Jayne  Webster 
 Disease Control and Vector Biology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and 
Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom; Malaria Consortium, Development House, 
56-64 Leonard Street, London EC2A 4LT, United Kingdom 
 Abstract.  Effective case management of uncomplicated malaria is a cornerstone of successful malaria control. With 
current calls for the global elimination of malaria, all strategies to control malaria need to reach the highest achievable 
level of effective implementation. A systematic literature review of all interventions to improve provider- and/or user-
side behavior in the prompt and appropriate treatment of uncomplicated malaria (with appropriate evaluation design and 
Roll Back Malaria outcome indicators) found 23 studies for review. Only 16 studies targeted providers, nine in the public 
sector and seven in the private sector. Just four interventions were conducted at national scale. These data suggest that 
very little is known about what interventions work in improving prompt and effective treatment of malaria. In the context 
of scaling up effective malaria control and malaria elimination plans and in increasing access to artemisinin combination 
therapies (ACTs), increased research in this area is crucial. 
 INTRODUCTION 
 Malaria is one of the leading causes of mortality worldwide, 
with over ninety percent of the burden falling on sub-Saharan 
Africa where it causes an estimated one million deaths each 
year; around seventy-five percent of these deaths are among 
children under five years of age. 1 
 Over the past few years there has been a substantial increase 
in the amount of attention and funding focused on attempts 
to reduce the burden of the disease and this focus has been 
accompanied by the development of various short and medium 
term targets for intervention coverage and disease reduction. 
The most recent development has been a call by the Bill and 
Melinda Gates Foundation, supported by the Director General 
of the World Health Organization, 2 to revive the long-term goal 
of malaria eradication. To start on the path toward achieving 
this goal, all of the current strategies available to control malaria 
need to reach the highest level of effective implementation, as 
outlined in the Global Malaria Action Plan and endorsed at the 
high level UN Millennium Development Goals meeting held 
in New York on 25 September. 3 One of the strategies that has 
been a corner stone of malaria control for the past 15 years is the 
prompt and effective treatment of episodes of malaria illness. 
For this particular strategy, the Roll Back Malaria Partnership 
(RBM) has set the target for 2010 of “80% of malaria patients 
are diagnosed and treated with effective anti-malarial medi-
cines, e.g., artemisinin-based combination therapies (ACT), 
within one day of the onset of illness.” 4 
 Data on progress toward this goal are fairly scarce, but infor-
mation in the 2008 World Malaria Report suggest that the mean 
proportion of children under five years of age with a fever that 
were treated with an anti-malarial drug in sub-Saharan Africa 
between 2006 and 2007 was 38%, although this varied across 
countries from 10% to 63%; just 3% of children were given ACT 
(range, 0.1–13%). 5 In addition, a large proportion of these treat-
ments were not started within 24 hours of the onset of fever, and 
may not therefore have been sufficiently timely to reduce the 
risk progression into severe life-threatening malaria. 
 Because prompt and effective treatment was first proposed 
as a malaria control strategy by the World Health Organization 
(WHO), 6 many interventions aimed at the various factors that 
influence prompt and effective treatment have been devel-
oped and implemented. These include interventions aimed at 
improving the prescription and dispensing practices of provid-
ers (public and private, formal and informal), and interventions 
aimed at the purchasing and adherence practices of anti-malar-
ial users and their caretakers. However, although many inter-
ventions have been implemented, the data from the World 
Malaria Report suggest that there is still some way to go before 
the RBM target for prompt and effective treatment is met. 
 Recent reviews have provided information on the factors 
that influence treatment seeking behavior 7 and behavior of 
certain categories of healthcare providers, 8–10 but to date no 
over-arching comparison has been made of the relative effec-
tiveness of the various interventions to improve these behav-
iors or their resulting impact on the diagnosis and effective 
treatment of patients with malaria within the first day of their 
illness. If we want to reach the RBM targets, we first need to 
identify those interventions that are most successful at improv-
ing access to prompt and effective malaria diagnosis and treat-
ment. The aim of this study is to conduct a systematic review of 
current evidence to identify those provider and user behavior 
interventions that are most effective in improving prompt and 
effective treatment of malaria. 
 METHODS 
 A systematic search of the published literature was con-
ducted using all combinations of the following search terms 
in the electronic databases PubMed, CAB Abstracts, African 
Journals Online, IBSS, and PsychINFO: malaria, fever, febrile, 
treatment, provider*, health personnel, home management, 
caretaker*, use*, intervention*, adherence, compliance, 
knowledge attitude practice, Africa. The last full search was 
conducted May 2007, although e-mail updates of potentially 
relevant articles continue to be received from Pubmed and 
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RBM. No further papers were included in the review after 
March 2008. The grey literature was accessed by searching 
websites of development agencies and organizations running 
malaria or health system strengthening projects/programs in 
sub-Saharan Africa. 
 All references were imported into the reference manager 
program EndNote 11 and any duplicates removed. The titles 
and abstracts of these references were checked for relevance 
and kept if they appeared to meet the objectives of the review. 
The remainder was read in full and reference lists of each 
paper were also cross-checked for additional relevant studies. 
Papers and reports were included only if they involved inter-
ventions designed to improve prompt and effective treatment 
of uncomplicated malaria or febrile illness through changes 
in anti-malarial provider and/or user behavior. The interven-
tions may have been targeted at treatment of malaria alone, 
or in combination with other diseases. Papers were excluded 
if they did not relate to malaria treatment, reported on severe 
malaria only, covered surveys of provider or user behavior 
without any intervention, related to chemoprophylaxis, mass 
drug administration, or traveler health. 
 Providers were defined as those responsible for dispens-
ing anti-malarials and were further categorized as public and 
private, and formal and informal or community-based. Public 
providers were those that operated within the governmental 
health service; private providers working in the for-profit or 
non-governmental (NGO) sectors, independent of govern-
ment funding. For the purposes of this review, formal public 
providers included health personnel: doctors, medical offi-
cers, nurses, and midwives; community-based public providers 
were voluntary members of the community, including com-
munity health workers or motivators (CHWs), schoolteach-
ers, and mothers ( Figure 1 ). Formal private providers were 
those that possess education and professional training, such as 
doctors, nurses, and pharmacists operating in the private-for-
profit or NGO sectors. Informal private providers were drug 
vendors, chemical sellers, and general shopkeepers that stock 
and sell medicines with or without regulation. Users were 
defined as consumers of anti-malarials; in the case of children 
under five years of age this also included their caretakers as 
appropriate. 
 To evaluate the outcomes, only studies with appropriate 
evaluation designs were included. Appropriate evaluation 
designs were defined as randomized controlled trials (RCTs), 
pre-post design with a control group, time series or repeated 
measure surveys, 11 pre-post study evaluations without a con-
trol group, and post-only evaluations with a control. These last 
two designs were included as it is possible to conclude that 
the intervention was plausible, or at least adequate, to achieve 
the outcomes measured even though in the absence of con-
trolling for all potential confounders the designs are not 
strong enough to infer direct causality between interven-
tion and outcome (as would be the case with a randomized-
controlled “probability” design). 12 Studies with evaluations 
conducted post-intervention only without a control group 
were excluded. 11 
 A standardized checklist was used to extract data from stud-
ies on malaria treatment outcomes measured before, during, 
and after implementation of the intervention. The informa-
tion extracted was based on the RBM-MERG (Monitoring 
and Evaluation Reference Group) indicator for early diagno-
sis and prompt treatment of malaria, which is “the percentage 
of patients with uncomplicated malaria getting correct treat-
ment at health facility and community levels, according to the 
national guidelines, within 24 hours of onset of symptoms.” 13 
“Correct treatment” was further divided into its component 
parts of correct anti-malarial (AM) given, at correct dosage 
and for the correct duration (according to national guidelines 
at the time of the study). We interpreted community level 
to include shops because these are an important source of 
anti-malarials outside of health facilities. Summary inclusion 
criteria are presented in  Box 1 . 
 RESULTS 
 A total of 769 papers were identified from the electronic 
database searches, of which 48 involved an intervention on 
prompt and effective treatment of fever ( Figure 2 ). A further 
10 such reports on intervention programs were identified from 
the grey literature. These 58 publications and reports involved 
a total of 63 study sites, as some studies involved multiple coun-
tries 14–16 or multiple sites in the same country. 16 Appropriate 
evaluation designs for assessing outcomes of the interventions 
were used in 40 of these 63 study sites. Twenty-seven of these 
40 studies reported their outcomes in the format of at least 
some part of the RBM-MERG indicator for early diagnosis 
and prompt treatment of malaria; four studies were excluded 
because of a lack of information on the number of the target 
group sampled (that is, the denominator used in assessing the 
outcome). The findings of the 23 studies, meeting all inclusion 
criteria, are summarized in  Table 1 . 
 One study was targeted at adults only, 17 four targeted all age 
groups, 18–21 and the remaining 18 were targeted at children (13 
specifically at children under five years of age). 14,15,22–32 However, 
most studies reported results in terms of child treatment 
 FIGURE 1. Public and private sector formal and informal/ 
community-based providers. 
1)  Interventions aimed at providers or users designed to 
improve prompt and effective treatment of fever in children 
under five years of age.
2)  Interventions were targeted at provider and/or user knowl-
edge and/or practices.
3)  Studies were evaluated using randomized controlled trials 
(RCTs), times series measurement, pre-post design with or 
without a control group, and post design with a control.
4)  Reported on at least one element of the Roll Back Malaria-
Monitoring and Evaluation Reference Group (RBM-
MERG) indicator on prompt and effective treatment.
5)  Presented both numerator and denominator information for 
outcomes.
BOX 1
 Inclusion criteria 
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 FIGURE 2. Overview of the study inclusion process. 
practices; this is what is reported in  Table 1 , with the exception 
of the one adults only study. 
 Measurement of full “prompt and effective treatment.”  Only 
two of the 23 studies reported the full RBM-MERG indicator, 
including a prompt treatment seeking dimension, and each 
of these reported on treatment within 24 hours of the onset 
of symptoms (see  Table 1 ). 28,33 The first of these is the Kilifi 
Shopkeeper Training program, which targeted both provider 
and user behavior. Impressive improvements in shopkeeper 
prescribing practices were achieved through training on the 
correct AM dispensing within the context of a change in AM 
policy from chloroquine (CQ) to sulfadoxine-pyrimethamine 
(SP) in Kenya. The proportion of shopkeepers prescribing the 
correct AM at the correct dose and duration increased from 
0% pre-intervention to 98% post-intervention ( P < 0.001). 33 
The increase in prompt treatment seeking and adherence 
among users, through improved counseling by shopkeepers 
and community sensitization events, was important but not as 
high (1.5% to 27.8%;  P < 0.001). The second study reporting 
results in the full RBM-MERG indicator format is an evalua-
tion of Uganda’s national Home-Based Management of Fever 
(HBMF) program. This program was also targeted at  improving 
provider and user behavior through the recruitment and train-
ing of community drug distributors (CDDs). The CDDs’ role 
is to presumptively treat fever in children under five years of 
age with free pre-packaged CQ-SP (Homapak) and educate 
mothers on correct treatment, and what to do if the child’s 
condition worsens. Evaluation of this program as it was rolled 
out in Kasese district showed a 13.5% increase in effective 
treatment among the intervention group ( P = 0.01). 28 
 Composite measurement of effective treatment (correct 
AM, dose, and duration).  Nine studies reported on a combina-
tion of three components of the RBM-MERG indicator, that 
is, appropriate anti-malarial given at the correct dose and for 
the correct duration (see  Table 1 ). 
 Of these, three studies were targeted at improving the behav-
ior of formal providers. Two of these were within the public 
sector and involved evaluations of Integrated Management of 
Childhood Illness (IMCI). 14,15 Both showed significantly higher 
levels of appropriate treatment of malaria in the facilities that 
had received the intervention compared with non-intervention 
facilities, although the improvements were greater in Tanzania 
(88% versus 25%) 14 than Uganda (49% versus 24%). 15 The 
other study involved the private sector, 17 specifically a one-
day seminar on rational drug use for private physicians, which
 achieved an overall increase in appropriate treatment of 9% 
by physicians receiving the intervention, although even this 
modest improvement was of borderline significance. 
 Three of the nine composite indicator studies focused 
on interventions aimed at improving user adherence and 
 therefore reported on user practices only. The intervention 
that involved pre-packaging anti-malarials produced impres-
sive improvements in user practices, achieving full adherence 
in 91% of the intervention group, compared with 42% of the 
control ( P < 0.001), by the use of pre-packaged CQ tablets 
rather than the CQ syrup usually given for small children. 22 
Conversely, the study by Okonkwo and others 29 showed that 
appropriate dosing and adherence could be achieved with 
CQ syrup by the inclusion of a pictorial insert describing the 
age-specific treatment regimen (full adherence of 52% with 
pictorial insert, compared with 37% without). When verbal 
instructions were also given alongside the pictorial insert, 
even greater improvements were achieved (further increasing 
adherence to 73%). This supports the need for clear visual and 
verbal instructions to be given with any drug treatment if it is 
to be taken correctly. 
 The third study was an RCT showing that supervised treat-
ment with chloroquine at the health facility achieved 86% full 
adherence, compared with 60% when treatment was given 
unsupervised at home. 25 Interestingly, there was no significant 
difference in treatment outcome, leading the investigators to 
conclude that mothers in this part of Guinea Bissau could “be 
trusted to give adequate anti-malarial medication to their chil-
dren at home.” 25 
 The remaining three composite indicator studies targeted 
both providers and users. All three involved public providers, 
one formal sector 21 and two community-based. 20,34 The study by 
Winch and others in Mali 20 had separate components targeted 
at the two groups, training providers (drug kit managers) in 
appropriate presumptive treatment of fever in children under 
five years of age (or referral of severe cases), with accompany-
ing community sensitization and education activities targeted 
at the users to increase their awareness and demand for the 
service. The additional training provided to the drug kit man-
agers in the intervention areas produced marginal improve-
ments in provider behavior, compared with the basic training 
provided in the control areas (59% and 48%, respectively; 
 P = 0.042). However, the improvements were much greater in 
user behavior (42% full adherence in intervention area, com-
pared with 1.5% in control;  P < 0.001). 
 The other two studies involved training providers to improve 
both their own practice and encourage adherence of their 
patients. 21,34 The study by Yeboah-Antwi and others 21 involved 
the use of pre-packaged drugs and resulted in appropriate 
treatment by 93.3% of intervention group providers (compared 
with 73.5% of control providers,  P < 0.001) and 82% of inter-
vention group users (compared with 60.5% of control users, 
 P < 0.001). The study by Afenyadu and others 34 built upon an 
existing and effective scheme of teachers trained to administer 
drugs to presumptively treat fever in school children. The intro-
duction of pre-packaged drugs further increased the correct 
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 TABLE 1 
 Summary of study outcomes according to the RBM-MERG case management indicator 
Recipient(s) Intervention
Scale of 
implementation
Evaluation 
design (period 
after int)
Single components of RBM-MERG 
indicator (Correct AM, or dose, or 
duration)
Composite RBM-MERG 
indicator (Correct AM, 
dose and duration, unless 
otherwise indicated)
Country and 
year of study
Public formal 
providers
Client-oriented, provider 
efficient (COPE) 
services. Provider-led 
self-assessment and 
planning.
Sub-district P+C (0 mo)  I/C (AM) Int: 61.9% 
(99/160), Comp: 50.7% 
(81/160) ( P = 0.06)
Guinea, 
Kenya, 
2001 35 
Integrated management 
of childhood illness 
(IMCI).
National P+C 
(max 3 yrs)
 I/C Int: 88% (149/169), 
Comp: 25% (34/135) 
( P < 0.001)
Tanzania, 
2000 14 
IMCI. National P+C (??)  I/C Int: 49% (68/139), 
Comp: 24% (53/221) 
( P < 0.001)
Uganda, 
2000 15 
In-service training of 
medical assistants. Two 
hour lecture.
National B/A−C 
(3–9 mo)
 B/A (Dose) 12.5% (4/32) to 
30.3% (10/33) ( P = 0.1)
Ghana, 
1987 18 
Private formal 
providers
One-day seminar on 
rational drug use 
(targeting adults only).
Sub-district B/A+C 
(0 mo)
 B/A+C Int: 13% (4/30) 
to 27% (8/30) Cont: 28% 
(22/78) to 33% (26/78) 
+9% in intervention 
group ( P = 0.09)
Uganda, 
?? 17 
Private informal 
providers
One-hour 1-to-1 session 
for drug sellers.
Sub-district; B/A+C 
(7 mo)
 B/A+C (AM) Int: 60% 
(12/20) to 100% (20/20) 
Cont: 40% (8/20) to 60% 
(12/20). +20% in interven-
tion group ( P = 0.02).
Tanzania, 
2004 27 
One-day training 
PMVs by peers + 
pre-packaged AMs.
District B/A−C 
(4 mo)
 B/A (AM) 48% (54/112) 
to 87% (87/100) 
( P < 0.001).  B/A 
(Dose) 11% (12/112) 
to 57% (57/100) 
( P < 0.001).
Nigeria, 
2003 23 
Negotiation sessions 
(based on self-
assessment and 
action planning).
District B/A−C 
(1–3 mo)
 B/A (AM) 2% (1/57) to 
73% (48/66) ( P < 0.001). 
 B/A (Dose) 0–50% 
(33/66) ( P < 0.001).
Uganda, 
2003 32 
Drug vendor-to-vendor 
education.
District P+C (6 mo)  I/C (AM) Int: 24% (37/157), 
Comp: 3% (6/202) 
( P < 0.001)  I/C (Dose) 
Int: 17% (27/157), Comp: 
1.5% (3/202) ( P < 0.001)
 Kenya, 
2000 31,36 
Users only RCT of pre-packaged 
CQ tablets vs. CQ 
syrup.
Sub-district RCT (0 mo)  I/C Int: 91% (141/155); 
Cont: 42% (61/144) 
syrup (X 2 = 78.3,  
P < 0.001).
Ghana, 
?? 22 
Village health motivators 
and drug vendors 
trained to educate 
mothers.
Sub-district B/A+C (??)  B/A+C, knowledge only 
(Dose: CQ for 1–3 
years ) Int: 23.2% (80/345) 
to 58.8% (203/345) Cont: 
20% (46/230) to 14.8% 
(34/230). +40.8% in 
intervention group 
( P < 0.001)
Zambia, 
2000 24 
Supervised vs. unsuper-
vised treatment.
Sub-district RCT (0 mo)  I/C Int: 86% (56/65); 
Cont: 60% (41/68) 
( P < 0.001).
Guinea 
Bissau, 
1995 25 
Health education program 
for mothers.
Sub-district B/A−C 
(3 mo)
 B/A, knowledge only (AM) 
2.3% (3/120) to 90% 
(103/114) ( P < 0.001).
The 
Gambia, 
1986 37 
Village health education 
meetings; free treatment 
at health post.
Sub-district B/A−C 
(12 mo)
 B/A, k nowledge only (AM) 
50% (92/185) to 81.7% 
(98/120) ( P < 0.001).
Cameroon, 
?? 26 
Three-armed RCT: CQ 
syrup only (control), 
CQ syrup with pictorial 
insert, CQ syrup 
with pictorial insert 
and verbal instructions.
Sub-district RCT (0 mo)  B/A Control 36.5% 
(69/190); pictorial 
insert 51.9% (117/225); 
insert and verbal 
instructions 73.3% 
(159/217). X 2 tests 
all significant at the 
0.1% level.
Nigeria, 
1996 29 
(continued)
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Recipient(s) Intervention
Scale of 
implementation
Evaluation 
design (period 
after int)
Single components of RBM-MERG 
indicator (Correct AM, or dose, or 
duration)
Composite RBM-MERG 
indicator (Correct AM, 
dose and duration, unless 
otherwise indicated)
Country and 
year of study
Neighbor-to-neighbor 
education.
District P+C (2 mo)  I/C (AM) Int: 49% (50/103), 
Comp: 30% (27/89) 
( P = 0.007)  I/C (Dose) 
Int: 29% (14/50), Comp: 
16% (4/27) ( P = 0.20)
Kenya, 
2002 19 
Public formal 
providers 
AND users
RCT of pre-packaged 
AM + paracetamol 
vs. routine prescribing 
methods.
Sub-district RCT (0 mo)  I/C Providers Int: 93.3% 
(293/314); Cont: 73.5% 
(250/340) ( P < 0.001). 
 I/C Users Int: 82% 
(137/167); Cont: 60.5% 
(92/152) ( P < 0.001).
Ghana, 
?? 21 
Public informal 
providers 
AND users
RCT of pre-packaged 
vs. loose CQ, given 
by schoolteachers for 
presumptive treatment 
of fever.
District RCT (0 mo)  I/C Providers Int: 97% 
(294/303); Cont: 
86.6% (206/238) 
( P < 0.001).  I/C Users 
Int: 88.5% (101/114) 
I; Cont: 88.9% (48/54) 
( P = 0.94)
Ghana, 
1998 34 
Training village drug kit 
managers.
District RCT (1–3 mo)  I/C Providers Int: 59% 
(89/151), Comp: 48% 
(63/131) ( P = 0.042, 
adj)  I/C Users Int: 
42% (64/151), Comp: 
1.5% (2/131) ( P < 0.001, 
adj)
Mali, 
2001 20 
Training mother educators 
to empower other 
women + pre-packaged 
drugs available from 
CHWs.
Province B/A−C 
(12 mo)
 B/A Users (AM) 25% 
(94/377) to 46% (175/380) 
( P < 0.001).  B/A Users 
(Dose) 3% (3/94) to 49% 
(86/175) ( P < 0.001).  B/A 
Users (Duration) 21% 
(20/94) to 72% (126/175) 
( P < 0.001)
Burkina 
Faso, 
1994 30 
Use of CDDs to educate 
mothers + free 
pre-packaged drugs.
National B/A+C 
(18 mo)
 B/A+C *  Users Int: 
7.4% (12/163) to 
13.5% (21/156) Cont: 
7.3% (7/96) to 0% 
(0/76). +13.5% in 
intervention group 
( P = 0.01)
Uganda, 
2004 28 
Private informal 
providers 
AND users
Training on correct AM 
dispensing practices 
and communication 
with clients.
Sub-district B/A−C (2 mo)  B/A Providers (Dose) 
31.8% (31/99) to 82.7% 
(165/199); to 89.9% 
(107/119) after refresher 
training ( P < 0.001).  B/A 
Users, knowledge only 
(Dose) 3.7% (4/109) to 
65.2% (118/181); to 75% 
(81/108) after refresher 
( P < 0.001).
Kenya, 
1996 40 
Training on correct AM 
dispensing practices 
and communication 
with clients + policy 
change from CQ to SP.
Sub-district B/A−C 
(12 mo)
 B/A Providers 0–98% 
(96/98) ( P < 0.001). 
 B/A Users * Sub-
location: 3% (13/388) 
to 27% (78/287) 
( P < 0.001). All areas: 
1.5% (10/681) to 27.8% 
(257/923) ( P < 0.001)
Kenya, 
1999 33 
 *  Composite indicator also includes treatment within 24 hours (i.e., the complete RBM-MERG indicator).  Abbreviations: adj = P value adjusted for clustering; AM = anti-malarial; ARI = 
acute respiratory infection; CDD = community drug distributor; CQ = chloroquine; CHW = community health worker; IMCI = integrated management of childhood illness; PMV = patent medi-
cine vendor; RCT = randomized controlled trial; SP = sulfadoxine-pyrimethamine; ?? = no information on year of study/start of intervention.  Evaluation designs: I/C = intervention vs. control 
(or comparison); B/A = before (baseline) vs. after implementation; B/A+C = before and after implementation with control; B/A−C = before and after implementation without control; Int = inter-
vention group; Cont = control group; Comp = comparison group. 
 TABLE 1 
 Continued  
treatment by teachers from 88.9% in the control schools to 
97% in the intervention schools ( P < 0.001). Less impact was 
seen on adherence by the children taking drugs over the week-
end, but this was already high at around 88%. 
 Measurement of individual components of effective treat-
ment (correct AM, or dose, or duration).  Twelve studies 
reported on one or more of the component parts of the RBM-
MERG indicator. Specifically, nine reported the correct AM, 
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nine the correct dose, one the correct duration; no study sepa-
rately reported on the prompt treatment seeking component 
(see  Table 1 ). 
 Two studies were found that reported on the results of 
interventions to improve formal provider behavior, both of 
which were in the public sector. The participatory approach 
used by Bradley and Igras 35 achieved borderline significance 
with 61.9% of the intervention group prescribing an appro-
priate anti-malarial, compared with 50.7% of control group 
( P = 0.06). However, the in-service training delivered in the 
other study 18 was of limited effectiveness, perhaps because 
of the short duration and didactic style of the interventions, 
which focused on lectures about rational drug use in accor-
dance with the national treatment guidelines. 
 Three of the four studies found that targeted informal pro-
viders (all in the private sector) appeared to produce much bet-
ter improvements in practice, achieving correct anti-malarial 
sales in 73–100% of intervention shops, an increase from low 
baseline levels. 23,27,32 This may reflect the more participatory 
nature of the interventions, which in two of the studies were 
designed with the input of the drug vendors themselves. 23,32 
Feedback from baseline observations of practice was used to 
facilitate self-assessment and action planning for performance 
improvements. Although positive improvements were found 
in the third study from a one-to-one session of just one-hour 
duration, 27 the scale of this study was very small, involving 
only 20 intervention and 20 control drug vendors. 
 The fourth study involving informal providers, which used 
a vendor-to-vendor education program, 31,36 also showed 
improvements in provider practice, although of a smaller mag-
nitude; 24% of intervention outlets dispensed the correct AM 
to a mystery shopper and 17% the correct dose, compared 
with 3% and 1.5% of comparison outlets, respectively. 
 Four studies were found that targeted only users, all of 
which used a health education approach to improve appropri-
ate treatment seeking for fever. Educating users alone does 
appear to be effective at changing their knowledge of the 
appropriate anti-malarial or dosage; 24,26,37 however, it has been 
frequently shown elsewhere that changes in knowledge do not 
necessarily correlate with changes in behavior. 38,39 The impact 
on actual behavior was only measured in one study, 19 and this 
showed significant effects for the use of correct AM (49% 
in the intervention area, compared with 30% in the non-
intervention area); there was no significant difference between 
intervention and comparison areas for using the correct dose. 
 A further two interventions were found that involved both 
providers and users; one involving the community-based pub-
lic sector, 30 and one the informal private sector. 40 Both studies 
had separate components targeted at the two groups, training 
of providers in appropriate presumptive treatment of fever in 
children under five years of age (community health workers/
drug distributors, or private drug sellers), with accompanying 
community sensitization and education activities targeted at 
the users to increase their demand for the services provided by 
trained providers. The inclusion of pre-packaged drugs 30 or spe-
cific training on communication skills 40 was additional compo-
nents of the intervention to facilitate appropriate behavior by 
both providers and users. The approach used by Pagnoni and 
others 30 in Burkina Faso was to empower mothers to actively 
seek the correct treatment for their children, with the CHWs 
simply holding the drug stocks and referring severe cases. This 
achieved significant improvements from baseline in use of 
correct AM (25–46%), correct dose (3–49%), and correct dura-
tion (21–72%). The shopkeeper training program, as reported 
by Marsh and others, 40 produced more impressive changes 
in provider behavior (83% gave correct dose compared with 
32% at baseline) as well as user knowledge (65% stated 
correct dose compared with 4% at baseline). Both of these 
indicators increased yet further following refresher training 
6 months after the initial intervention (90% correct dose given 
by providers, 75% correct dose reported by users). 
 DISCUSSION 
 The overwhelming finding from this systematic review 
is that there are very few data on available interventions to 
improve the appropriate case management of uncomplicated 
malaria and even fewer, which have been evaluated in such 
a manner that the impact can be reasonably ascribed to the 
intervention. The majority of studies were excluded as they did 
not report on an intervention, generally reporting instead on 
current practices of providers 41–43 and/or users 44–46 ; a number of 
papers found were literature reviews 7,11,47,48 or related to chang-
ing national drug policies 49 or wider health systems issues. 8,50 
Approximately 37% (23/63) of studies that did include inter-
ventions to improve prompt and effective treatment of malaria 
were excluded as they did not include an appropriate evalua-
tion method for assessing the outcomes of the intervention. 
 The authors appreciate the difficulties in conducting evalua-
tions of interventions that may be part of multifaceted programs 
rather than formally designed experiments, and acknowledge 
that such evaluations may have certain important lessons to 
contribute. However, we were concerned with determining the 
 effectiveness of interventions, which demands a certain stan-
dard of evaluation design. Studies using post-only with con-
trol and pre-post no control designs were included because 
they provide evidence of the “plausibility” or “adequacy” of 
an intervention, respectively; in the absence of controlling for 
all potential confounders the designs are not strong enough to 
infer direct causality between intervention and outcome (as 
would be the case with a randomized-controlled “probability” 
design), however it is possible to conclude that the interven-
tion was plausible, or at least adequate, to achieve the out-
comes measured. 12 If these study designs were excluded, only 
24 (rather than 40) interventions would remain (of which 10 
would be classed as “probability” studies and 14 as “plausi-
bility”), with the majority of those lost being program eval-
uations, which are important because they demonstrate the 
effectiveness of interventions under “real-life” conditions (as 
opposed to controlled intervention trials). 
 Our choice to only include studies reporting results in the 
format of the RBM-MERG indicator reduced the evidence 
base by a further 43%. It is important to note that a number 
of the studies (among those both excluded and included by 
this criterion) were conducted or published before the RBM-
MERG indicator was developed. However, prompt and effec-
tive treatment has been a key malaria control strategy for many 
years, and we felt the decision was justified given the neces-
sity for all four components (correct AM, correct dose, correct 
duration, prompt access) to achieve effective case management 
of uncomplicated malaria. Additionally, the use of a common 
indicator(s) facilitates comparison of results among studies. 
Some flexibility in reporting was kept—studies reporting on 
single components of the indicator were included. Indeed, had 
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we only included studies that reported the full indicator (with 
or without an element of prompt treatment seeking); only 11 
studies would have remained for analysis and discussion. 
 The RBM indicator, although useable for both provid-
ers and users, means slightly different things in each group. 
Among providers the indicator assesses whether the correct 
anti-malarial is prescribed (based on the national guidelines at 
the time), and whether it is prescribed at the correct dose and 
for the correct duration. In users this indicator may be used 
to assess what was prescribed by the provider, what the user 
actually received, and whether they completed the treatment 
(i.e., adhered) at the correct dose in a prompt manner. 
 The magnitude of impact of the 23 interventions on prompt 
and effective treatment included in our analysis, varies greatly 
between the groups targeted, methods used, and scale of 
intervention. 
 Overall, only 16 studies were found involving interventions 
targeted at providers, nine in the public sector and seven in 
the private sector. Once this is further broken down into for-
mal and informal/community-based providers within each cat-
egory, the number of studies providing evidence on possible 
interventions becomes even smaller (Public sector: 5 formal, 
4 community-based; private sector: 1 formal, 6 informal). 
 In-service training of formal providers, using the methods 
that have been adopted to date, does not appear to have had 
much impact in the included studies. Often such in-service 
training uses a didactic approach, presenting the case for ratio-
nal drug use without accounting for wider determinants of 
practice, such as patient demand for certain drugs/services, or 
the influence of peers. 51 In addition, without follow-up super-
vision any improvements gained by training have been shown 
to severely deteriorate within a period of 12 months. 18 The 
approach adopted in IMCI training, which involves more inter-
active learning with the chance for clinical practice, has shown 
positive, albeit mixed, results. For example, the effectiveness 
of IMCI on provider treatment of malaria was almost twice 
as high in Tanzania as in Uganda. Reasons for this may have 
been quality of training and/or supervision, and other factors 
such as health worker morale. 15 Emphasizing rational drug use 
and improved provider-client communication during pre-ser-
vice training, as well as on-site refresher training using opinion 
leaders or district-level staff and supportive supervision, may 
be more effective methods for improving the case management 
of malaria in the formal sector. 11 A series of cross-sectional 
studies of health worker performance generally found that 
reported experience of in-service training was not significantly 
associated with correct treatment of uncomplicated malaria 52–54 ; 
in one of the studies, in-service training was associated with 
appropriate malaria case management, but only when com-
bined with other interventions such as job aides and frequent 
supervision. 55 Similar mixed findings were reported by a wider 
review of (non-malaria-specific) interventions to improve 
health-worker performance. 56 Regardless, any improve-
ments in prescribing practices can only be maintained if ade-
quate supplies of effective anti-malarial drugs are available. 57 
Further investigation of the role and performance of formal 
private providers in the case management of malaria is par-
ticularly needed and, in countries where they are an important 
source of treatment, increasing their involvement in interven-
tions should be considered. 
 In general, the interventions targeted at informal provid-
ers showed greater impacts on behavior, particularly those 
involving the private sector, i.e., shopkeepers and drug ven-
dors. The more successful of these involved the drug vendors 
in the design and content of training, and found that gaining 
the trust and commitment of informal private providers was 
extremely important to the program’s success, because they 
operate largely outside the government regulatory frame-
work and can be suspicious of external attention. Our find-
ings support those discussed in a recent review of the role 
of medicine sellers in malaria treatment by Goodman and 
others, 9 namely that successful interventions included buy-
in from medicine sellers and community members, use of a 
combination of approaches (including visual job aides such 
as dosing charts and community sensitization), and mainte-
nance of training and supervision. Informal private provid-
ers, such as drug vendors and general shopkeepers, are widely 
used for fever and malaria treatment in sub-Saharan Africa, 
often forming the first (and in some cases, only) source of 
care. 58 Their potential for achieving effective and, particu-
larly, prompt treatment of uncomplicated malaria should not 
be underestimated. 
 The common model used in the community-based pub-
lic sector is that of training community volunteers (including 
mothers and schoolteachers) in the presumptive treatment of 
fever in under fives with pre-packaged anti-malarials, coupled 
with community sensitization activities. Significant but modest 
improvements in treatment behavior have been shown; how-
ever, there is still considerable room for improvement in this 
approach. To realize the potential of CHW programs, there 
must be sufficient training and supervision, as well as suffi-
cient payment or incentives for their health extension work, 
particularly as their tasks and responsibilities are increased. 59 
Interestingly, the study involving schoolteachers was highly 
effective in improving both user and provider practice— 
perhaps because of the authoritative nature of the teacher-
pupil relationship and structured school environment. 
 Fourteen of the interventions had at least some compo-
nent targeting users, seven involving users only and seven 
also including a provider-side component. As presented in 
the results section, two general approaches to improving user 
malaria treatment practices have been used: 1) health educa-
tion messages or campaigns, and 2) interventions that specifi-
cally provide information on how to take prescribed/dispensed 
anti-malarials, including pre-packaging, and pictorial and ver-
bal instructions. The second of these approaches has achieved 
much greater improvements in behavior, indeed the health 
education programs were generally only evaluated in terms 
of changes in knowledge, which is insufficient when change in 
practice is the ultimate goal. 
 Our analysis suggests that, among the included studies, 
pre-packaging of drugs is one of the most effective ways of 
increasing adherence to guidelines by both users and provid-
ers in all sectors. A recent Cochrane review, 60 evaluating the 
effectiveness of unit dose packaged treatments for malaria on 
cure and treatment adherence, found insufficient evidence to 
determine the effectiveness of unit dose packaging on treat-
ment outcomes, but some evidence to suggest that the unit 
dose packaging together with prescriber training and patient 
information did improve patient adherence. However, the 
authors cautioned that the data were derived from studies 
with methodological limitations. 
 Where significant changes in behavior have been measured, 
only two studies provide information on the full RBM-MERG 
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indicator and in these studies the changes, although signifi-
cant, still leave at least two thirds of the population without 
prompt, effective treatment (including dose and duration), 
well short of the 80% RBM target for 2010. These findings 
have significant implications not only for individual morbid-
ity and mortality, but also for broader public health efforts to 
eradicate malaria. That is, unless individuals who are ill with 
malaria are able to promptly access the correct treatment and 
complete an adequate dose then the individual is at risk of 
severe illness and death, and parasites continue to circulate in 
the population. 
 A further concern is the sustainability of behavior change. 
Many of the post-intervention surveys were carried out imme-
diately or very soon after the training or intervention had been 
conducted (16 of 21 studies with this information were com-
pleted within 12 months of the intervention, 12 within 3 months; 
see  Table 1 ). It is possible that some of the changes in behavior 
and/or knowledge would lose significance if measured again, 
for example a year later. Sustainability of behavior change is 
crucial if the intervention is to provide any lasting benefits. 
A number of the studies implemented their interventions with 
sustainability in mind and conducted longer duration follow-
up. For example, the Shopkeeper Training Program in Kilobit 
conducted annual refresher workshops and found a sustained 
improvement in provider practices with 98% fully adhering to 
treatment guidelines up to 4 years after the program started. 
User knowledge was also sustained, but unfortunately the 
long-term practices of users were less impressive with only 
27% fully adhering by the end of the study. 33 The Homapak 
study in Uganda was conducted 18 months after implemen-
tation, and supports the need for activities to improve the 
longer-term impact with only 13.5% of the study population 
accessing a complete course of effective anti-malarials within 
24 hours of onset of symptoms. 28 However, because no indica-
tion of CDD performance was reported, it is unclear whether 
this was a result of sub-optimal performance of the CDDs or 
lack of appropriate sensitization and education of the com-
munities. It is possible that the modest impact is related to 
the constraints accompanying implementation of the inter-
vention at national scale, e.g., a lack of personnel to provide 
adequate supervision and sensitization. The CHW training in 
Burkina Faso showed significant improvements in user adher-
ence when the supply chain and supervision was still under the 
management of the research team, but was seriously impeded 
when handed over to the routine health system and problems 
with stock-outs were experienced. 30 These findings reinforce 
the notion that any interventions to change provider and user 
behavior need to take account of the broader context within 
which these changes are being implemented (e.g., staff con-
straints, supply constraints, access constraints). 
 A final issue that arises from this review is the scope of 
implementation of the interventions. Only four of the included 
studies involved interventions implemented at the national 
scale. In the case of the HBMF and IMCI interventions, the 
studies were evaluating a national strategy using a district-
level phased-in approach. Although a number of the studies 
were carried out at district level, which in many countries is 
now the level of implementation of national policy, there is 
still a need for national-level co-ordination and supervision, 
especially given the wide variation in capacity between differ-
ent districts within a country. This is of particular relevance in 
the context of elimination discussions because high levels of 
effective case management (in combination with other strate-
gies) will need to be achieved and maintained nationally (and 
indeed regionally); a country cannot afford to have poorly 
performing districts or neighbors. 
 CONCLUSION 
 The importance of improving effective case management of 
malaria in the context of intensive malaria control and elimi-
nation cannot be overestimated. The results from this review 
show that many interventions aimed at improving malaria 
case management have been undertaken, but assessment of 
their effectiveness is severely constrained by limitations in the 
methods used to evaluate their success. In order that lessons 
from future programs might provide evidence on the effective-
ness of alternative interventions, the methods used to evaluate 
these interventions should be sufficient to assign at least ade-
quacy that the intervention has contributed to an increase in 
the relevant outcome, or plausibility that improved outcomes 
were a result of the intervention. 
 Making definitive conclusions from the findings of this 
review on “best” interventions is difficult, given the diver-
sity of groups targeted, scale of implementation, and evalu-
ation designs and methods used. It is clear that while some 
effective interventions to improve malaria treatment do 
exist, significantly more information is needed to provide 
definitive evidence. In particular, there is a large gap in 
the evidence on “what works” to change formal public and 
private sector provider behavior and even less evidence is 
available on how to sustain any behavior change achieved. 
Although we recognize the need to increase access to effec-
tive anti-malarial through the community and the retail sec-
tor, the quest for identification of effective interventions for 
improving access within hospitals and clinics should be a 
major priority. 
 We know practically nothing about ways in which to improve 
user practices as the majority of evaluations of interventions 
targeting users have measured only changes in knowledge. 
We should acknowledge the wealth of evidence that change 
in knowledge does not necessarily lead to change in practices, 
and call for measures of change in practices as the relevant 
outcome of interventions for increasing prompt and effective 
treatment of improved malaria control. 
 If in the short term we want to reduce morbidity and morta-
lity from malaria and in the longer term to move towards elim-
ination, sufficient attention needs to be paid to the broader 
context, particularly health system constraints, that are likely 
to impact upon the effectiveness and sustainability of inter-
ventions to improve prompt and effective treatment, particu-
larly when taken to scale. 
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